Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ: UTHR )

370.58 +0.14 (+0.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%. 
Via StockStory
Topics Stocks
Exposures US Equities
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
From United Therapeutics Corporation
Via Business Wire
How Is The Market Feeling About United Therapeutics?
Via Benzinga
$1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces Successful World’s First UKidney Transplant
From United Therapeutics Corporation
Via Business Wire
How Is The Market Feeling About United Therapeutics?
Via Benzinga
Earnings Outlook For United Therapeutics
Via Benzinga
Decoding 7 Analyst Evaluations For United Therapeutics
Via Benzinga
The Analyst Landscape: 7 Takes On United Therapeutics
Via Benzinga
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
From United Therapeutics Corporation
Via Business Wire
$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Peering Into United Therapeutics's Recent Short Interest
Via Benzinga
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
A Look Into United Therapeutics Inc's Price Over Earnings
Via Benzinga
U.S. Stock: United Therapeutics Corp
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. 
Via Talk Markets
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
Key Takeaways From United Therapeutics Analyst Ratings
Via Benzinga
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
From United Therapeutics Corporation
Via Business Wire
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.